Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Rossio

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Cancer Treatment Reports|November 1, 1978
Overview of thymosin activityG D Marshall, T L Low, G B Thurman, et al.
Blood|April 1, 1986
Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseasesC R Faltynek, G L Princler, J L Rossio, et al.
Journal of Medical Primatology|September 23, 2003
Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallengeJ D Lifson, M Piatak, A N Cline, et al.
AIDS Research and Human Retroviruses|November 14, 1998
Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccineL O Arthur, J W Bess, E N Chertova, et al.
Hybridoma|January 1, 1985
The generation of stable human T-cell hybridomas which constitutively produce interleukin-2 and chemotactic factorK A Foon, J L Rossio, R W Schroff, et al.
Journal of Biological Response Modifiers|February 1, 1986
Comparative evaluation of multiple lymphoid and recombinant human interleukin-2 preparationsG B Thurman, A E Maluish, J L Rossio, et al.
Journal of the National Cancer Institute|April 19, 1989
Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerationsW J Urba, J W Clark, R G Steis, et al.
Cancer Research|June 1, 1992
Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effectsC H Ewel, W J Urba, W C Kopp, et al.
Journal of Medical Primatology|October 23, 2002
Whole inactivated SIV virion vaccines with functional envelope glycoproteins: safety, immunogenicity, and activity against intrarectal challengeJ D Lifson, M Piatak, J L Rossio, et al.
Journal of Virology|September 12, 1998
Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteinsJ L Rossio, M T Esser, K Suryanarayana, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Cancer Treatment Reports|November 1, 1978
Overview of thymosin activityG D Marshall, T L Low, G B Thurman, et al.
Blood|April 1, 1986
Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseasesC R Faltynek, G L Princler, J L Rossio, et al.
Journal of Medical Primatology|September 23, 2003
Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallengeJ D Lifson, M Piatak, A N Cline, et al.
AIDS Research and Human Retroviruses|November 14, 1998
Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccineL O Arthur, J W Bess, E N Chertova, et al.
Hybridoma|January 1, 1985
The generation of stable human T-cell hybridomas which constitutively produce interleukin-2 and chemotactic factorK A Foon, J L Rossio, R W Schroff, et al.
Journal of Biological Response Modifiers|February 1, 1986
Comparative evaluation of multiple lymphoid and recombinant human interleukin-2 preparationsG B Thurman, A E Maluish, J L Rossio, et al.
Journal of the National Cancer Institute|April 19, 1989
Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerationsW J Urba, J W Clark, R G Steis, et al.
Cancer Research|June 1, 1992
Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effectsC H Ewel, W J Urba, W C Kopp, et al.
Journal of Medical Primatology|October 23, 2002
Whole inactivated SIV virion vaccines with functional envelope glycoproteins: safety, immunogenicity, and activity against intrarectal challengeJ D Lifson, M Piatak, J L Rossio, et al.
Journal of Virology|September 12, 1998
Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteinsJ L Rossio, M T Esser, K Suryanarayana, et al.
Pageof 5